Study of AKY-1189 for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has spread or is too advanced to remove, confirmed by a biopsy or cell sample.
- You have at least one tumor that can be measured on a CT scan.
- You are well enough to be up and about (ECOG score 0 or 1).
- Your organs are working well enough to handle the treatment.
- You have had cancer progression after your last treatment for metastatic disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Urothelial Carcinoma Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.